LeadStory

CNBC

Merck to buy Verona for $10B ahead of Keytruda patent expiration

CNBC · Just In
CNBC
CNBC
Just In

CNBC's Angelica Peebles reports on themes emerging in the pharma space.

BreakdownGenerated by LeadStory AI
  • Merck is buying Verona Pharma for about $10 billion to diversify beyond Keytruda. 5s
  • Keytruda's patent expiration is expected to create a $30 billion revenue gap for Merck. 26s
  • Verona's COPD drug is already on the market, with $70 million in first-quarter sales. 55s
  • The acquisition aligns with a trend of pharma companies buying commercial-stage firms. 1m 0s
  • Verona's drug may have further sales potential through additional indications. 1m 29s
Business